Co-Diagnostics (CODX) Tops Q2 EPS by 43c

Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of ($0.23), $0.43 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• DA Davidson Reiterates Buy Rating on Tractor Supply Company (TSCO) Amid Soft Q2 Expectations
• BofA expects Apple to top analyst expectations on July 30
• Nebius Group (NBIS) PT Raised to $410 at Northland